Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / NAVB - Epizyme's NDA Accepted And Other News: The Good Bad And Ugly Of Biopharma


NAVB - Epizyme's NDA Accepted And Other News: The Good Bad And Ugly Of Biopharma

The FDA Accepts Epizyme Marketing Application

Epizyme (EPZM) reported that the FDA has accepted its marketing application regarding Tazverik. The treatment is being developed for managing patients with relapsed or refractory lymphoma who have received at least two prior lines of systemic therapy. The FDA is scheduled to provide its decision by June 18th. The treatment has been granted Priority Review and the company’s application is deemed to be a supplemental NDA.

Tazverik was approved for epithelioid sarcoma in adults and children 16 or older in January 2020. The drug is

Read more ...

Stock Information

Company Name: Navidea Biopharmaceuticals Inc.
Stock Symbol: NAVB
Market: OTC
Website: navidea.com

Menu

NAVB NAVB Quote NAVB Short NAVB News NAVB Articles NAVB Message Board
Get NAVB Alerts

News, Short Squeeze, Breakout and More Instantly...